Fujirebio (Japan) acquires biotech innovator from Flanders
Established in 2011 by four veterans from Ghent-based biotech pioneer Innogenetics, ADx Neurosciences specializes in tailor-made antibodies and diagnostic methods for pharmaceutical companies. The Flanders-based company develops, among other things, antibodies capable of detecting early signs of Alzheimer’s disease in spinal fluid and blood samples. Led by CEO Koen Dewaele, ADx Neurosciences is now being acquired by Fujirebio, a Japanese biotech multinational.
Following the EUR 40 million acquisition, the Ghent-based biotech company will become a wholly-owned subsidiary of Fujirebio, which itself is part of Japanese-listed H.U. Group Holdings. Fujirebio is a world leader in the development of in vitro diagnostics (IVD) tests on samples taken from the human body. Founded in 1950, the company has over 50 years of experience in the production and commercialization of IVD tests.
Fighting neurodegenerative diseases
ADx Neurosciences will continue its current business activities and keep on serving its existing customers. The Flanders-based company’s product pipeline mainly consists of biomarkers to estimate brain deterioration.
Fujirebio is committed to investing in the development of diagnostic kits for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. We are excited to work with the ADx Neurosciences team to expand the global market for neurodegeneration biomarker testing.
With the acquisition of ADx Neurosciences, Fujirebio will strengthen its ties with Flanders’ business and research ecosystem for life sciences & health. Want to find out more about the companies and organizations that make up this ecosystem? Head to Flanders360 to schedule a virtual tour or check out our industry overview.
Reported by
newspaper De Tijd
